In hepatocellular carcinoma (HCC) CD73 was shown to contribute to resistance to Lenvatinib, a VEGF inhibitor, through AKT overactivity which resulted in increased SOX9 expression and stemness of HCC cells (13). Here, VEGFA is linked to hepatocellular carcinoma.